May 2017May 2017
New Product - Stivarga
Stivarga (regorafenib) is an oral antitumour agent that potently blocks multiple protein kinases, including kinases involved in tumour angiogenesis (VEGFR1, 2, 3, TIE2), oncogenesis (KIT, RET, RAF-1, BRAF), and the tumour microenvironment (PDGFR, FGFR). In particular, regorafenib inhibits mutated KIT, a major oncogenic driver in gastrointestinal stromal tumours (GIST) and thereby blocks tumour cell proliferation. Stivarga is indicated for the treatment of metastatic colorectal cancer that has been previously treated with fluoropyrimidine, oxaliplatin and irinotecan based chemotherapy, an anti-VEGF therapy, and, if RAS wild type, an anti-EGFR therapy. Stivarga is also indicated for the treatment of unresectable or metastatic GIST in patients who progressed on or are intolerant to prior treatment with imatinib and sunitinib. Severe drug induced liver injury with fatal outcome has been observed in patients receiving Stivarga. Monitor hepatic function prior to and during treatment. Stivarga is supplied as 40 mg tablets in packs of 84’s (3 x 28’s).
Copyright © MIMS Australia Pty Ltd. All rights reserved.
MIMS Australia
Level 2, 1 Chandos Street
St Leonards NSW 2065
Phone: 1800 800 629
info@mims.com.au
www.mims.com.au